PROPS – A multi-centre, open-label, randomised controlled trial to test the non-inferiority of a fixed dose combination (FDC) pill strategy versus standard primary care for secondary prevention of stroke.
Standard treatment for people who have suffered a stroke or mini-stroke (transient ischaemic attack, or TIA) usually includes taking blood pressure lowering medication, cholesterol lowering medication and aspirin. The aim of these treatments is to reduce the chance of having another stroke. Usually, these are all taken as separate tablets.
PROPS is a clinical trial looking at two different ways of taking stroke medication, in a primary care setting. In this trial, these medicines have been combined together into one capsule called Trinomia. We want to find out whether taking the Trinomia capsule is at least as good as taking standard separate medications. This will tell us whether it has a role in the secondary prevention of vascular events (e.g. stroke or heart attack) in older people who have already had a stroke or TIA.
The PROPS trial is part of a larger programme of research funded by the British Heart Foundation and the Stroke Association. The trial is sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. Trinomia is supplied free of charge by Ferrer International.